The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge.
Published: 25 Feb 2026
Citation: Karatlı S, Gül Ö, Kısa Ü, Tekin E, Ergül B. Are decreased serum Maresin 1 levels predictive of cholangiocarcinoma? J Curr Hematol Oncol Res. 2026;4(1):1-6.
Published: 25 Feb 2026
Citation: Aydeniz G, Esen R, Doğan A. Evaluation of the response and adverse effects of intravenous iron therapy in patients with iron deficiency anemia: a single-center experience. J Curr Hematol Oncol Res. 2026;4(1):7-11.
Published: 25 Feb 2026
Citation: Kayran MM, Aldemir MN, Aydemir O, Erdem M, Erzen Ş, Ebinç S. Evaluation of demographic and clinical data of patients diagnosed with lung cancer: a single-center experience. J Curr Hematol Oncol Res. 2026;4(1):12-17.
Published: 25 Feb 2026
Citation: Akanıl Fener N. SMARCA2 and SMARCA4 expression in epithelioid pleural mesothelioma: association with inflammatory microenvironment. J Curr Hematol Oncol Res. 2026;4(1):18-24.
Published: 25 Feb 2026
Citation: Özgören İ, Yavaşoğlu İ. Development of common variable immunodeficiency in a patient with severe aplastic anemia: a case report. J Curr Hematol Oncol Res. 2026;4(1):25-26.
Published: 25 Feb 2026
Citation: Mutlu Sütcüoğlu B, Kansu Çelik H, Akarsu E. Early-stage cervical leiomyosarcoma and carcinosarcoma with long-term disease-free survival after surgery alone: a dual case report. J Curr Hematol Oncol Res. 2026;4(1):27-30.
Published: 30 Aug 2023
Citation: Barış Iİ, Büyükbayram H. ß-catenin expression in myelodysplastic syndromes and myeloproliferative neoplasms in bone marrow, in relation to CD34 and CD117 status. J Curr Hematol Oncol Res. 2023;1(3):54-58.
Published: 26 Feb 2023
Citation: Kaya A, Berber İ, Kuku İ, et al. Effect of tyrosine kinase inhibitor and conventional chemotherapy on COVID-19 antibody level in hematological patients. J Curr Hematol Oncol Res. 2023; 1(1): 1-4
Published: 12 Feb 2024
Citation: Çelik S, Kaynar L. Get two with one: bevacizumab treatment in hereditary hemorrhagic telangiectasia with concomitant cirrhosis. J Curr Hematol Oncol Res. 2023; 1(1): 15-17.